Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Current Assets (2020 - 2025)

Historic Current Assets for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $501.7 million.

  • Tarsus Pharmaceuticals' Current Assets rose 4048.73% to $501.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.7 million, marking a year-over-year increase of 4048.73%. This contributed to the annual value of $356.7 million for FY2024, which is 3926.66% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Current Assets of $501.7 million as of Q3 2025, which was up 4048.73% from $474.4 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Current Assets high stood at $501.7 million for Q3 2025, and its period low was $176.0 million during Q4 2021.
  • Its 5-year average for Current Assets is $285.6 million, with a median of $250.3 million in 2022.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Current Assets soared by 11004.13% in 2021 and then tumbled by 2669.26% in 2023.
  • Tarsus Pharmaceuticals' Current Assets (Quarter) stood at $176.0 million in 2021, then rose by 28.09% to $225.4 million in 2022, then grew by 13.65% to $256.1 million in 2023, then soared by 39.27% to $356.7 million in 2024, then skyrocketed by 40.65% to $501.7 million in 2025.
  • Its last three reported values are $501.7 million in Q3 2025, $474.4 million for Q2 2025, and $480.8 million during Q1 2025.